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N-substituted pyrrole-based scaffolds as potential anticancer lead structures 
 
Abstract 
Undoubtedly, efficient cancer treatment is a significant challenge for the scientific community the last 
decades. Despite tremendous progress made towards this direction, there are still efforts needed to 
discover new anticancer drugs. In this work, a series of N-substituted pyrrole-based scaffolds have been 
synthesized and evaluated for antiproliferative activity against a panel of cancer cell lines (L1210, 
CEM and HeLa). Furthermore, in order to discover new scaffolds as antivirus agents all the examined 
compounds were evaluated for antivirus activity against different types of DNA and RNA viruses. The 
key feature of the above structures is the existence of an aromatic ring with at least one hydrogen-
bonding donor and acceptor group. Results have shown interesting cytostatic activity for three of the 
synthesized compounds (1, 3 and 9). Especially, compound 1, containing a tropolone ring, proved to be 
the most promising scaffold (IC50:10-14 μΜ) for the development of novel potential anticancer agents. 
In addition, compound 1 has shown interesting antivirus activity as a scaffold against a variety of 
viruses.  
Keywords 
N-substituted pyrroles, scaffolds, antiproliferative agents, antiviral activity, aromatic ring, hydrogen-
bonding donor and acceptor group. 
 
1. INTRODUCTION 
 
Cancer is a leading cause of death worldwide both in developing and developed countries. It is 
accounted that about 7.6 million people died from cancer in 2008 and it is estimated that deaths 
globally are projected to continue to rise to over 13.1 million in 2030 [1]. Although there are many 
types of cancer, there is one defining feature in all of them - the abnormal and uncontrolled cell 
division. “Cancer can be caused by both external factors such as tobacco, chemicals, radiation and 
infectious organisms and internal factors such as inherited mutations, hormones, immune conditions 
and mutations that occur from metabolism”[2]. 
Heterocycles can serve as useful tools in medicinal chemistry to manipulate lipophilicity, polarity and 
hydrogen bonding capacity of molecules, which may lead to improved pharmacological, 
pharmacokinetic, toxicological and physicochemical properties of drug candidates and ultimately drugs 
[3]. Currently, a great number of heterocyclic templates are used as anticancer or antivirus agents and 
many efforts have been still in progress in this way. Among heterocyclic compounds, the pyrrole 
moiety is a prominent chemical motif, found widely in natural products, biologically important 
molecules, drugs and advanced materials. “This five-membered nitrogen-containing heteroaromatic 
ring, planar and electron-rich, is a useful recognition element in many biological contexts-forming 
hydrogen bonds, coordinating metals and providing stacking interactions” [4].  
Thus, a series of N-substituted pyrrole-based scaffolds (Figure 1) have been designed, synthesized and 
evaluated for their antiproliferative activity against three different cancer cell lines. Additionally, in 
order to obtain potent antivirus agents as scaffolds, the antiviral activity of the examined compounds 
were tested in vitro. The key structural component of the above substitutes is the existence of an 
aromatic ring with at least one hydrogen-bonding donor and acceptor group. “Hydrogen bonding is a 
directional and moderately strong intermolecular force. Compounds that present multiple hydrogen 
bond donor and acceptor groups have proven to be extremely important in creating new self-assembled 
structures” [5]. It is also known that hydrogen bonds are used to stabilize and determine the structure of 
macromolecules like proteins and nucleic acids, as well as they contribute to ligand recognition by 
biological receptors [6]. 
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2. RESULTS AND DISCUSSION 
2.1. Chemistry 
Two different methodologies were followed for the synthesis of the pyrrole derivatives (Scheme 1). 
The first one, employed for compounds 1-6, utilized a modified Clauson-Kaas-type reaction for the 
formation of the pyrrole ring [7]. Commercially-available arylamines and 5-aminotropolone [8] were 
treated with 2,5-dimethoxytetrahydrofuran and 4-chloropyridinium hydrochloride as a catalyst to afford 
the respective compounds. Alternatively, the appropriate aryl iodides were converted to 7 and 8, by 
means of a modified Ullman-type coupling reaction [9]. In this modification, 1,3-difluoro-4-iodo-2-
methoxybenzene [10] and 1-(benzyloxy)-4-iodo-1H-pyrazole [11] were coupled with pyrrole, after 
treatment with CuI and trans-N,N -tetramethylcyclohexane-1,2-diamine as catalysts and K3PO4 as the 
base.  
End products 9-11 were obtained after demethylation of the respective methyl ethers 5-7 with 
pyridinium hydrochloride [12]. In contrast, the benzyl group of compound 8 was selectively cleaved 
after treatment with equal amounts of Pd/C and ammonium formate at 0°C, to afford 12 [9] (Scheme 
2).  
Finally, the synthesis of compounds 13 [13] and 14 [14] is described in the related articles.  
 
2.2. Biological Evaluation 
Compounds 1 to 4, and 9 to 14 have been evaluated for their cytostatic activity against murine 
leukemia L1210, human CD4+ T-lymphocyte CEM and human cervix carcinoma HeLa cells. 
From the obtained results (Table 1) it is obvious that compounds 2, 4 and 10-14 presented negligible, if 
any antiproliferative activity (IC50 > 100 µM), in contrast to compounds 1, 3 and 9. Especially, the 
tropolone derivative (1) was consistently found to be the most cytostatic in all examined cancer cell 
lines (IC50: 10-14 µM) followed by 3 (IC50: 22-33 µM) and 9 (IC50: 32-100 µM). It was interesting to 
reveal the markedly lower cytostatic activity of the closely-related 4 (versus 3) and 10 (versus 9) 
derivatives. Also, 1, 3 and 9 were not cytotoxic in normal (primary) confluent human lung fibroblast 
(HEL) cell cultures (MCC50 > 100 µM). This may point to a very structure-selective interaction of the 
drug molecules with their cytostatic target. The cytostatic potential of 1 was only 5- to 10-fold lower 
than the established 6-mercaptopurine anticancer drug. It is generally accepted, that compounds with a 
tropolone skeleton might have a broad spectrum of biological activities such as an antimicrobial, 
antifungal, phytogrowth-inhibitory and cytotoxic effect on mammalian tumor cells [15]. In fact, 
Ononye et al, recently found that a series of tropolone derivatives was found to be potent and selective 
histone diacetylase inhibitors [16]. However, the molecular target of 1 is currently not known. It should 
also be noticed that 1 exerted a modest anti-HSV-1, -HSV-2 and –vaccinia virus activity in HEL cell 
cultures (EC50: 27-40 µM) whereas none of the other compounds showed appreciable antiviral activity 
against a broad variety of DNA and RNA viruses (data not shown). 
3. CONCLUSION 
In summary, a series of N-substituted pyrrole-based scaffolds were examined for antiproliferative 
activity against three cancer cell lines as well as for antiviral activity. Among the studied compounds, 
compound 1 which has a tropolone ring, demonstrated the most potent activity against all cancer cell 
lines (IC50:10-14 μΜ). Also, compound 3 showed pronounced cytostatic activity, while compound 9 
exhibited cytostatic activity only against CEM and HeLa. Furthermore, from the examined compounds, 
only 1 presented to be a promising antiviral agent as scaffold. In general, the findings suggested that 
compounds 1, 3 and 9 could represent interesting scaffolds for the development of novel potential 
anticancer agents. Further modifications of these scaffolds are currently under consideration. 
4. EXPERIMENTAL METHODS 
4 
 
4.1. Chemistry 
General: All reagents were purchased from Sigma–Aldrich Co. and used without further purification, 
except for the solvents used for flash chromatography and recrystallization. 1H NMR spectra were 
recorded on a Bruker AM 300 at 300 MHz and chemical shifts are given in d referenced to the residual 
solvent peak. 13C NMR spectra at 75.5 MHz on the same spectrometer, using chloroform-d (CDCl3), 
dimethylsulfoxide-d6 (DMSO-d6). Melting points are uncorrected and were determined in open glass 
capillaries using a Mel-Temp II apparatus. A Shimadzu 2010-EV LC/MS was used for obtaining a 
LC/MS spectrum, using methanol or mixture of methanol-water (formic acid 0.1%) as solvents. All 
LC-MS spectras were obtained under isocratic elution in a reversed phase C18 column. Microanalyses 
were performed on a Perkin-Elmer 2400-II Analyzer. Flash column chromatography was carried out on 
a Merck silica gel 60 plate (230–400 Mesh ASTM). Reaction progress was followed by thin-layer 
chromatography (Fluka Silica gel/TLC-cards). All solvents used for column chromatography and/or 
recrystallization were routinely distilled prior to use. Petroleum ether refers to the fraction with bp 40o–
60o C. The known compounds 13 and 14 were synthesized as previously described [12, 13] for the 
purpose of evaluation of their antiproliferative activity. 
4.2. General Method for Synthesis of Compounds 1-6: The modified Clauson-Kaas Type 
Reaction  
To a solution of the appropriate arylamine (29.4 mmol) in dioxane (210 ml), 2,5-
dimethoxytetrahydrofuran (5.36 g,  40.6 mmol) and 4-cloropyridinium hydrochloride (6.79 g,  45.3 
mmol) were added. The mixture was refluxed under a nitrogen atmosphere for 3 h. After removal of 
the solvent under reduced pressure, the residue was treated with 50 ml of CH2Cl2 and filtered. The 
filtrate was concentrated in vacuo and the residue was purified with flash column chromatography, 
using various solvent mixtures as eluent. In the case of 1, after removal of the solvent under reduced 
pressure, the residue was treated with 50 ml of EtOAc and filtered. EtOAc was removed under reduced 
pressure from the filtrate and the residue was treated with 10% NaHCO3 (20 ml) and extracted with 
EtOAc (2 x 50 ml). The aqueous phase was cooled (ice bath) and acidified with 10% HCl, and 
extracted with EtOAc (2 x 50 ml). The combined organic extracts were washed with a saturated NaCl 
solution, dried over anhydrous Na2SO4 and concentrated under reduced pressure.  
4.2.1. 2-hydroxy-5-(1H-pyrrol-1-yl)cyclohepta-2,4,6-trienone (1)  
Yield: 63% after recrystallization by AcOEt/petroleum ether; m.p.: 184-187°C; 1H NMR (300 MHz, 
CDCl3/DMSO-d6): δ=  6.20-6.29 (m, 2H), 7.04-7.09 (m, 2H), 7.22-7.31 (m, 2H), 7.43-7.56 (m, 2H), 
7.99 (s, 1H); 13C NMR (75.5 MHz, CDCl3/DMSO-d6): δ= 116.03, 124.92, 129.46, 135.31, 144.27, 
175.21; LC–MS: m/z= 188 [M+H]+, 186 [M-H]+. Anal. Calcd. for C11H9NO2 (%): C, 70,58; H, 4.85; N, 
7.48. Found: C, 70.77; H, 4.48; N, 7.49.  
4.2.2. 5-(1H-pyrrol-1-yl)-1,3,4-thiadiazole-2-thiol (2) 
Yield: 42% after flash column chromatography with petroleum ether/AcOEt mixture (10:1); m.p.: 185-
187°C; 1H NMR (300 MHz, CDCl3/DMSO-d6): δ= 6.20-6.30 (m, 2H), 6.94-7.06 (m, 2H), 7.35 (s, 1H). 
13C NMR (75.5 MHz, CDCl3/DMSO-d6): δ= 112.85, 119.44, 153.32, 185.21; LC–MS m/z: 182 (M-
H)+. Analytical sample was obtained by recrystallization from CH2Cl2/petroleum ether. Anal. Calcd. 
for C6H5N3S2 (%): C, 39.32; H, 2.75; 22.93. Found: C, 39.72; H, 2.86; N, 22.81.  
4.2.3. 5-(1H-pyrrol-1-yl)-1H-indazole (3)  
Yield: 71% after flash column chromatography with CH2Cl2; m.p.: 181-184°C; 1H NMR (300 MHz, 
CDCl3/DMSO-d6): δ= 6.10-6.19 (m, 2H), 6.85-6.96 (m, 2H), 7.18-7.31 (m, 1H), 7.35-7.46 (m, 1H), 
7.47-7.55 (m, 1H), 7.82-7.91 (m, 1H), 12.5 (s, br, 1H); 13C NMR (75.5 MHz, CDCl3/DMSO-d6): δ= 
109.81, 111.14, 111.77, 119.96, 121.09, 123.15, 133.74, 134.59, 138.7; LC–MS m/z= 184 (M+H)+,182 
(M-H)+. Analytical sample was obtained by recrystallization from CH2Cl2/petroleum ether. Anal. 
Calcd. for C11H9N3(%): C, 72.11; H, 4.95; N, 22.94. Found: C, 72.44; H, 5.13; N, 23.21.  
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4.2.4. 6-(1H-pyrrol-1-yl)-1H-indazole (4) 
Yield: 74% after flash column chromatography with CH2Cl2; m.p.: 201-202°C; 1H NMR (300 MHz, 
CDCl3/DMSO-d6): δ= 5.89-6.04 (m, 2H), 6.72-6.80 (m, 2H), 6.84-6.92 (m, 1H), 7.08-7.17 (m, 1H), 
7.33-7.47 (m, 1H), 7.58-7.72 (m, 1H), 12.37 (s, br, 1H); 13C NMR (75.5 MHz, CDCl3/DMSO-d6): δ= 
100.87, 110.32, 114.78, 119.53, 120.66, 121.19, 132.94, 138.58, 140.23; LC–MS m/z= 184 (M+H)+, 
182 (M-H)+. Analytical sample was obtained by recrystallization from CH2Cl2/petroleum ether. Anal. 
Calcd. for C11H9N3 (%): C, 72.11; H, 4.95; N, 22.94. Found: C, 72.33; H, 4.89; N, 22.78.  
4.2.5. 6-methoxy-2-(1H-pyrrol-1-yl)benzo[d]thiazole (5) 
Yield: 70% after flash column chromatography with petroleum ether/AcOEt mixture (25:1); m.p.: 118-
120°C. 1H NMR (300 MHz, CDCl3): δ= 3.89 (s, 3H), 6.40-6.45 (m, 2H), 7.03-7.12 (m, 1H), 7.24-7.32 
(m, 1H), 7.40-7.46 (m, 2H), 7.79 (d, J=8.9 Hz, 1H); 13C NMR (75.5 MHz, CDCl3): δ= 55.68, 104.73, 
112.16, 114.98, 119.77, 122.47, 133.12, 145.27, 157.16; LC–MS m/z= 231 (M+H)+, 254 (M+H+Na)+, 
229 (M-H)+. Analytical sample was obtained by recrystallization from Et2O/petroleum ether. Anal. 
Calcd. for C12H10N2OS.0.05Et2O(%): C, 62.62; H, 4.52; N, 11.97. Found: C, 62.89; H, 4.58; N, 12.04.  
4.2.6. 4-methoxy-2-(1H-pyrrol-1-yl)benzo[d]thiazole (6) 
Yield: 90% after flash column chromatography with petroleum ether/AcOEt mixture (23:1); m.p.: 88-
90°C; 1H NMR (300 MHz, CDCl3): δ= 3.70 (s, 3H), 5.95-6.15 (m, 2H), 6.51-6.70 (m, 1H), 6.95-7.05 
(m, 2H), 7.09-7.26 (m, 2H); 13C NMR (75.5 MHz, CDCl3): δ= 56.13, 107.69, 112.44, 113.45, 115.54, 
120.24, 125.49, 125.88, 128.63, 133.47, 140.96, 152.71, 158.36; LC–MS m/z= 231 (M+H)+, 254 
(M+H+Na)+, 229 (M-H)+. Analytical sample was obtained by recrystallization from Et2O/petroleum 
ether. Anal. Calcd. for C12H10N2OS.0.05Et2O(%): C, 62.62; H, 4.52; N, 11.97. Found: C, 62.57; H, 
4.61; N, 11.59.  
4.3. Synthesis of 1-(2,4-difluoro-3-methoxyphenyl)-1H-pyrrole (7) 
To a stirred solution of 1,3-difluoro-4-iodo-2-methoxybenzene (448 mg, 1,66 mmol) in dry toluene (2 
ml), pyrrole (93 mg, 1.39 mmol), trans-tetramethylcyclohexane-1,2-diamine (40 mg, 0.28 mmol) and 
K3PO4 (620 mg, 2.92 mmol) were added. A catalytic amount of CuI (13 mg, 0.07 mmol) was, then, 
suspended and the mixture was refluxed for 24 h under N2 atmosphere. The reaction mixture was 
cooled in room temperature, diluted with 4 ml of CH2Cl2 and filtered through a plug of silica. 
Additional CH2Cl2 (70-90 ml) were used to wash the silica and the solvents were removed under 
reduced pressure. Further purification of the resulting residue was achieved by silica gel flash column 
chromatography, using a mixture of petroleum ether/AcOEt (50:1) as eluent and gave viscous 
yellowish oil. Yield: 53%; 1H NMR (300 MHz, CDCl3): δ= 4.09 (s, 3H), 6.33-6.45 (m, 2H), 6.90-7.11 
(m, 4H). 13C NMR (75.5 MHz, CDCl3): δ= 61.91, 109.86, 111.60, 117.83, 121.32, 126.48, 147.50, 
155.34; LC–MS m/z= 210 (M+H)+, 208 (M-H)+. 
4.4. General method for the synthesis of compounds 9-11: Cleavage of methyl ethers 
To pyridine hydrochloride (6.94 g, 60 mmol) that had been preheated at 210°C for 10 min, the 
appropriate methyl ether (2.6 mmol) was added and the mixture was stirred under a nitrogen 
atmosphere at 210°C for 1 h. The reaction mixture was then poured into ice and the resulting solution 
was extracted with Et2O (3 x 50 ml). The combined organic phases were washed with saturated NaCl 
solution, dried over anhydrous MgSO4 and removed under reduced pressure. The resulting residue was 
purified with flash column chromatography, using a mixture of petroleum ether/AcOEt (ratios from 
12:1 to 22:1) as eluent.  
4.4.1. 2-(1H-pyrrol-1-yl)benzo[d]thiazol-6-ol (9)  
Compound 9 was prepared from 5. Yield: 60%; m.p.: 217-220°C; 1H NMR (300 MHz, CDCl3/DMSO-
d6): δ= 6.27-6.35 (m, 2H), 6.96 (dd, J=2.4 Hz, J= 8.8 Hz, 1H), 7.17-7.24 (m, 1H), 7.29 (s, 1H), 7.32-
7.40 (m, 2H), 7.64 (d, J=8.8 Hz, 1H); 13C NMR (75.5 MHz, CDCl3/DMSO-d6): δ= 106.94, 112.13, 
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115.93, 119.79, 122.36, 133.06, 144.26, 154.87, 156.66; LC–MS m/z= 217 (M+H)+, 215 (M-H)+. 
Analytical sample was obtained by recrystallization from Et2O/petroleum ether. Anal. Calcd. for 
C11H8N2OS (%): C, 61.09; H, 3.73; N, 12.95. Found: C, 61.32; H, 3.75; N, 13.05.  
4.4.2. 2-(1H-pyrrol-1-yl)benzo[d]thiazol-4-ol (10) 
Compound 10 was prepared from 6. Yield: 58%; m.p.: 147-148°C; 1H NMR (300 MHz, 
CDCl3/DMSO-d6): δ= 6.30 (s, br, 1H), 6.36-6.45 (m, 2H), 7.00 (d, J= 25.1 Hz, 1H), 7.27 (dd, J=7.9 Hz, 
J= 22.7 Hz, 1H), 7.40-7.48 (m, 2H); 13C NMR (75.5 MHz, CDCl3/DMSO-d6): δ= 111.35, 112.86, 
120.04, 122.37, 125.96, 128.45, 132.21, 139.81, 149.14, 158.23; LC–MS m/z= 217 (M+H)+, 240 
(M+H+Na)+, 215 (M-H)+. Analytical sample was obtained by recrystallization from high boil 
petroleum ether (80-110°C). Anal. Calcd. for C11H8N2OS (%): C, 61.09; H, 3.73; N, 12.95. Found: C, 
61.24; H, 3.81; N, 13.13.  
4.4.3. 2,6-difluoro-3-(1H-pyrrol-1-yl)phenol (11) 
Compound 11 was prepared from 7. Yield: 62%; m.p.: 76-78°C; 1H NMR (300 MHz, CDCl3): δ= 6.33-
6.38 (m, 2H), 6.85-6.91 (m, 1H), 6.93-7.00 (m, 3H), 7.26 (s, 1H); 13C NMR (75.5 MHz, CDCl3): δ= 
110.08, 114.71, 114.78, 121.40, 144.04, 145.95, 148.70, 150.64; LC–MS m/z= 194 (M-H)+. Analytical 
sample was obtained by recrystallization from CH2Cl2/petroleum ether. Anal. Calcd. for C10H7F2NO 
(%): C, 61.54; H, 3.62; N, 7.18. Found: C, 61.47; H, 3.28; N, 7.13.  
4.5. Synthesis of 4-(1H-pyrrol-1-yl)-1H-pyrazol-1-ol (12)  
To a stirred solution of 8 (368 mg, 1.54 mmol) in 28 ml of dry MeOH/THF mixture (1:1), ammonium 
formate (542 mg, 8.6 mmol) was added and the reaction mixture was cooled to 0°C under N2 
atmosphere. Palladium on carbon 10% (542 mg, 5.0 mmol) was, then, suspended to the cold mixture, 
which was stirred further for 1h. Afterwards, the reaction mixture was diluted with 20 ml of MeOH and 
filtered through a Whatman filter paper, which retained the Pd/C. Additional MeOH (ca. 100 ml) was 
used to wash the Pd/C and the combined solvents were removed under reduced pressure. The residue 
was dissolved in equal parts of H2O/AcOEt (200 ml), the organic layer was collected, dried over 
Na2SO4 and concentrated in vacuo. The resulting residue was purified by recrystallization from 
CH2Cl2/petroleum ether. Yield: 50%; m.p.: 162-165°C; 1H NMR (300 MHz, CDCl3/DMSO-d6): δ= 
6.15-6.27 (m, 2H), 6.75-6.86 (m, 2H), 7.15-7.24 (m, 1H), 7.36-7.46 (m, 1H), 7.59 (s, br, 1H); 13C NMR 
(75.5 MHz, CDCl3/DMSO-d6): δ= 109.49, 114.83, 120.21, 123.43, 123.73; LC–MS m/z= 148 (M-H)+. 
Anal. Calcd. for C7H7N3O.0.1CH2Cl2 (%): C, 54.09; H, 4.60; N, 26.66. Found: C, 54.17; H, 4.61; N, 
26.63.  
4.6. Biological Methods 
4.6.1. Antiviral Activity Assays [17,18]  
“The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) 
strain KOS, thymidine kinase-deficient (TK−) HSV-1 KOS strain resistant to ACV (ACVr), herpes 
simplex virus type 2 (HSV-2) strain G, vaccinia virus Lederle strain, respiratory syncytial virus (RSV) 
strain Long, vesicular stomatitis virus (VSV), Coxsackie virus B4, parainfluenza virus 3, influenza 
virus A (subtypes H1N1, H3N2), influenza virus B, Reovirus-1, Sindbis virus, Punta Toro virus, 
human immunodeficiency virus type 1 strain IIIB and human immunodeficiency virus type 2 strain 
ROD. The antiviral, other than anti-HIV, assays were based on inhibition of virus-induced 
cytopathicity in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), human 
epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK). Confluent cell cultures in 
microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to 
infect 50% of the cell cultures) in the presence of varying concentrations of the test compounds. Viral 
cytopathicity was recorded as soon as it reached completion in the control virus-infected cell cultures 
that were not treated with the test compounds. Antiviral activity was expressed as the EC50 or 
compound concentration required to reduce virus-induced cytopathogenicity by 50%”. 
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4.6.2. Anti-HIV Activity Assays [17,18] 
“Inhibition of HIV-1(IIIB)- and HIV-2(ROD)-induced cytopathicity in CEM cell cultures was measured 
in microtiter 96-well plates containing 3 × 105 CEM cells/ml infected with 100 CCID50 of HIV per 
milliliter and containing appropriate dilutions of the test compounds. After 4−5 days of incubation at 
37°C in a CO2-controlled humidified atmosphere, CEM giant (syncytium) cell formation was examined 
microscopically. The EC50 (50% effective concentration) was defined as the compound concentration 
required to inhibit HIV-induced giant cell formation by 50%”. 
4.6.3. Cytostatic Activity Assays [17,18] 
“All assays were performed in 96-well microtiter plates. To each well were added (5−7.5) × 104 tumor 
cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine 
leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 
37°C in a humidified CO2-controlled atmosphere. At the end of the incubation period, the cells were 
counted in a Coulter counter. The IC50 (50% inhibitory concentration) was defined as the concentration 
of the compound that inhibited cell proliferation by 50%”. 
4.6.4. Cytotoxic Activity Assay [17,18] 
Confluent human lung fibroblast (HEL) cultures in 96-well microtiter plates were exposed to serial 
dilutions of the test compounds (i.e. 100, 20, 4, 0.8 µM). After 3 days of incubation at 37°C, 
microscopical detectable alterations of cell morphology were examined. 
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 Figure 1: N-substituted pyrrole-based scaffolds 
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Scheme 1: Reagents and Conditions: (a) 2,5-dimethoxytetrahydrofuran, 4-
chloropyridine hydrochloride, 1,4-dioxane, reflux, 3h. 
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Scheme 2: Reagents and Conditions: (a) K3PO4, CuI, trans-N, N'-
tetramethylcyclohexane-1,2-diamine, toluene, reflux, 24h. 
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Scheme 3: Reagents and Conditions: (a) pyridine hydrochloride, 210oC, 1h. 
(b) HCOONH4, Pd/C, MeOH/THF, 0oC, 1h. 
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Table 1. Antiproliferative and Cytotoxic Activity of Compounds against a Panel of Cancer Cell Lines and 
Primary fibroblasts 
 
Compound IC50a (µM) MCCb (µM) 
 L1210 CEM HeLa HEL 
PEG102 (1) 13 ± 4 10 ± 1 14 ± 3 >100 
PPN16 (2) >250 >250 >250 >100 
PPN10 (3) 24 ± 3 33 ± 8 22 ± 1 >100 
PPN11 (4) 100 ± 8 107 ± 23 47 ± 4 >100 
PPN15 (9) 100 ± 2 49 ± 14 32 ± 3 >100 
PPN14 (10) 112 ± 1 104 ± 20 107 ± 3 >100 
PPN12 (11) 120 ± 2 ≥250 110 ± 5 >100 
PPN17 (12) >250 >250 >250 >100 
PPN13 (13) 194 ± 23 216 ± 47 ≥250 >100 
PEG100 (14) >250 >250 >250 >100 
5-Fluorouracil 0.33 ± 0.17 18 ± 5 0.54 ± 0.12 - 
6-Mercaptopurine 2.8 ± 1.1 2.8 ± 1.3 1.1 ± 0.1 - 
 
a 50% inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%. Data are 
the mean average of 2-3 independent experiments (± SD). 
b Minimal cytotoxic concentration or compound concentration required to affect and alter microscopically detectable 
human lung fibroblast HEL cell morphology. 
 
